Corpus Intelligence IC Memo — HARLINGEN MEDICAL CENTER 2026-04-26 12:34 UTC
IC Memo — HARLINGEN MEDICAL CENTER
Investment Committee Memorandum | TX | 112 beds | Grade C | EBITDA uplift $8.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HARLINGEN MEDICAL CENTER

CCN 450855 | CAMERON, TX | 112 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

HARLINGEN MEDICAL CENTER is a 112-bed suburban community hospital in CAMERON, TX with $111.4M in net patient revenue and a -0.4% operating margin. The hospital serves a payer mix of 17.6% Medicare, 2.6% Medicaid, and 79.7% commercial.

Thesis: Undervalued. Our ML models identify $8.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -0.4% to 6.9% (+736bps).

Net Revenue HCRIS$111.4M
Current EBITDA COMPUTED$-468K
Operating Margin COMPUTED-0.4%
Occupancy HCRIS66.8%
Revenue / Bed COMPUTED$995K
Net-to-Gross HCRIS13.6%
Distress Probability ML42.0%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
189
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -0.4% places it above the state median. Among 189 size-comparable peers (56-224 beds), the median margin is 2.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (56-224), prioritizing same-state peers. 189 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HARLINGEN MEDICAL CENTER (Target)TX112$111.4M-0.4%
DRISCOLL CHILDRENS HOSPITALTX215$694.3M29.4%
ROUND ROCK HOSPITALTX165$681.4M8.7%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%
COVENANT CHILDRENS HOSPITALTX181$410.3M15.5%
COLLEGE STATION HOSPITALTX135$397.7M-0.9%
MEMORIAL HERMANN KATYTX196$381.4M13.3%
CHILDRENS HOSPITAL OF SAN ANTOTX174$376.5M-2.8%
MEDICAL CITY FORT WORTHTX209$375.9M22.9%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $8.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$2.3M+210bp18mo
Cost to Collect4.5%2.5%$2.2M+200bp12mo
Denial Rate Reduction12.0%6.5%$2.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$1.4M+122bp9mo
Clean Claim Rate88.0%96.0%$71K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$2.3M
Cost to Collect
$2.2M
Denial Rate Reduction
$2.2M
A/R Days Reduction
$1.4M
Clean Claim Rate
$71K
Total EBITDA Uplift$8.2M
Current EBITDA$-468K
+ RCM Uplift+$8.2M
Pro Forma EBITDA$7.7M
Current Margin-0.4%
Pro Forma Margin6.9%
WC Released (1x)$4.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-720K$78.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-720K$86.6M0.00x-100.0%
Bull Case9.0x11.0x$-648K$113.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-648K$123.5M0.00x-100.0%
Bear Case11.0x10.0x$-792K$38.2M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-792K$41.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 189 hospitals with 56-224 beds
  • Same-state prioritization (n=190)
  • Comp margins: P25=-9.0% / P50=2.7% / P75=11.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.